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The character of EGFR signals can influence cell fate but mechanistic insights into intestinal EGFR-Ras signalling are limited. Here we show that two distinct Ras nucleotide exchange factors, RasGRP1 and SOS1, lie downstream of EGFR but act in functional opposition. RasGRP1 is expressed in intestinal crypts where it restricts epithelial growth. High RasGRP1 expression in colorectal cancer (CRC) patient samples correlates with a better clinical outcome. Biochemically, we find that RasGRP1 creates a negative feedback loop that limits proliferative EGFR-SOS1-Ras signals in CRC cells. Genetic Rasgrp1 depletion from mice with either an activating mutation in KRas or with aberrant Wnt signalling due to a mutation in Apc resulted in both cases in exacerbated Ras-ERK signalling and cell proliferation. The unexpected opposing cell biological effects of EGFR-RasGRP1 and EGFR-SOS1 signals in the same cell shed light on the intricacy of EGFR-Ras signalling in normal epithelium and carcinoma.
Thirty per cent of metastatic cancers carry somatic KRAS mutations (termed KRAS
MUT here), such as KRAS G12D , which impair RasGAPmediated Ras inactivation, culminating in high levels of active KRAS-GTP and strong proliferative signals [1] [2] [3] . Colorectal cancer (CRC) is the third most common cancer in the United States 4 and tumours carry KRAS MUT in approximately 40% of patients 5 . Epidermal growth factor receptor (EGFR) expression is widespread in CRC (ref. 5) but clinical trials with anti-EGFR blocking antibodies or EGFR kinase inhibitors have been disappointing for CRC, particularly when tumours carry KRAS MUT (refs 6,7) . In contrast, such therapies have been successful in non-small-cell lung cancer patients with EGFR mutations 7 . The most intuitive explanation for failure of anti-EGFR therapy is that constitutive activity of KRAS MUT bypasses regulation mediated by EGFR. However, EGFR signalling is essential for KRAS MUT -driven pancreatic ductal carcinoma (PDAC) in mice 8, 9 and in the clinic erlotinib is beneficial for some PDAC patients 10 . EGFRRas signalling in intestinal progenitor cells is believed to balance proliferation and differentiation 11 , although mechanistic insights are limited.
Ras is GTP-loaded by Ras guanine nucleotide exchange factors (RasGEFs) in response to receptor signals 3 . The amplitude and duration of EGFR signalling to Ras and its downstream target MAPK (MAP kinase) affects cell fate; EGF stimulation of rat adrenal pheochromocytoma (PC-12) cells leads to transient Ras activation and proliferation whereas NGF stimulation results in sustained Ras-MAPK activation, exit from mitosis, and differentiation 12 .
Lymphocytes also exhibit distinct Ras-MAPK activation patterns 13, 14 and deficiency of Rasgrp1 or Sos1 RasGEFs impact T-cell development at distinct stages [15] [16] [17] [18] . We have shown that the type of RasGEF dictates Ras activation patterns; RasGRP1 (Ras guanine nucleotide releasing protein-1) transmits analogue Ras signals whereas SOS1 (Son of Sevenless-1) transmits digital Ras signals 14 . Digital Ras activation relies on allosteric activation of SOS, accomplished by Ras-GTP binding to an allosteric pocket in SOS (ref. 19) , creating a positive feedback loop in cells 14, 20, 21 . We established that RasGRP1 is structurally distinct from SOS1 and lacks allosteric activation by Ras-GTP (refs 19,22) and postulated that these RasGEFs may play distinct roles in EGFR signalling in the intestine. Here we reveal that RasGRP1 opposes EGFR-SOS1 signals and suppresses proliferation in normal intestinal epithelial cells as well as in epithelium carrying KRas G12D or Apc Min/+ mutations. Our results reveal significant insights into the EGFR-Ras pathway and how nuances in EGFR-Ras signals impact cell biology. 25, 64 . Various CRC cell lines used in our study are noted on the plot. (e) RasGRP1 mRNA expression z-scores versus copy number value in human colon cancer patients (n = 276) from the TCGA Colorectal Adenocarcinoma data set 25, 65 . Each dot represents a sample with no mutation on RasGRP1 (blue), missense mutation (red, n = 5) or nonsense (yellow). (f) RasGRP1 mRNA expression z-scores plotted against KRAS mRNA expression z-scores for the 276 patient samples in e. Colours represent mutational status 25 . (g) RasGRP1 mRNA expression determined by Taqman PCR on liver metastases samples surgically removed from 30 CRC patients. (h) Oncomine analysis was performed to examine RASGRP1 expression in human colon adenocarcinoma and normal colon using online TCGA microarray data. RASGRP1 levels are decreased in colon adenocarcinoma compared with normal tissues. Results are shown as box plots representing the median, 25th and 75th percentiles as boxes, as well as 10th and 90th percentiles as bars, using GraphPad Prism. RASGRP1 levels in colon adenocarcinoma (n = 102, maxima, 0.318; minima, −3.766) are decreased (fold change, −2.244; P = 6.73 × 10 −10 (Student's t-test)) compared with normal tissue (n = 19, maxima, 0.794; minima, −1.582).
RESULTS

RasGRP1 expression in CRC
We used a DT40 B-cell model engineered to express EGFR (ref. 23) to explore the effects of RasGEF deficiency on EGFR-induced ERK activation. We found that ERK activation is not only reduced in EGF-stimulated DT40 cells that lack SOS RasGEFs but also in cells lacking RasGRPs (Fig. 1a,b) . SOS1 is ubiquitously expressed but RasGRP1 has specific expression patterns in cells of the immune system, skin and brain 15 . Rasgrp1-deficient mice have a T-cell development defect 17 , suggesting an immune cell-centric role for Rasgrp1. However, Rasgrp1 was identified in fibroblast transformation assays 24 , arguing that Rasgrp1 affects the function of multiple cell lineages. Our DT40 data implied that RasGRP1 might play an unappreciated role in EGFR signalling and epithelial cell lineages.
We next used cBioPortal 25 to mine The Cancer Genome Atlas (TCGA) for RasGRP1 and plotted RasGRP1 expression levels in 60 cancer cell lines (NCI-60 panel 26 ). High expression of this RasGEF occurs in T-cell leukaemia lines MOLT4 and CEM, as we previously reported 27 , but low-level RasGRP1 expression exists in various CRC cell lines (Fig. 1c) . RasGRP1 messenger RNA levels covered a dynamic range in 56 established CRC cell lines (Fig. 1d ) and in 276 CRC patient samples (Fig. 1e) . The RasGRP1 expressed typically consists of the wild-type (WT) sequence, and variants in RasGRP1 are rare in CRC samples (5 out of 276, Fig. 1e ). Similar ranges of RasGRP1 expression levels are observed for KRAS WT . Data are depicted as bar graphs with mean score ± s.e.m. obtained from n = 5 mice for WT and n = 6 mice for Rasgrp1 −/− . * P = 0.0115 (unpaired t-test). (d,e) Representative images of short-(2 h, d) and long-term (48 h, e) in vivo BrdU-labelling assays in the colon of WT or Rasgrp1 −/− mice. Scale bars, 100 µm. (f) Quantification and statistical analysis of BrdU-positive cells in the colon. n = 150 crypts pooled from 3 WT mice and n = 150 crypts pooled from 3 Rasgrp1 −/− mice were counted to obtain mean ± s.e.m. * * * P < 0.0001 (Wilcoxon matched-pairs signed rank test). (g) Long-term (48 h) in vivo BrdU labelling in the small intestine. Scale bars, 100 µm. (h) Positioning of BrdU-positive cells in the small intestine. n = 120 crypt-villus axes pooled from 3 WT mice and n = 120 pooled from 3 Rasgrp1 −/− mice were counted. Data are represented as percentage of cells per position ± s.e.m. (i) Representative images of small intestines of WT-and Rasgrp1 −/− mice stained for cleaved caspase-3 (red) and DAPI (blue). Scale bars, 100 µm. (j) Quantification of cleaved caspase-3-positive cells in the small intestine from mice with the indicated genotype. n = 360 transversally sectioned villi pooled from 3 WT mice and n = 360 pooled from Rasgrp1 −/− mice were counted to obtain the mean ± s.e.m. graphed as positive cells per villus. * P < 0.05 (unpaired t-test). (k,l) Alcian blue staining (k) to visualize goblet cell presence in the small intestine (duodenum). Scale bars, 100 µm. (l) Data represent mean ± s.e.m. n = 150 transversally sectioned villi pooled from 3 WT mice and n = 150 pooled from 3 Rasgrp1 −/− mice were counted. * * * P < 0.001 (Wilcoxon t-test).
CRC (Fig. 1f) , an observation we confirmed in liver metastases of CRC patients (Fig. 1g) . We next used the Oncomine database (www.oncomine.org) and uncovered that the RasGRP1 expression levels in colonic adenocarcinomas are lower when compared with normal colonic epithelium (Fig. 1h) , suggesting that RasGRP1 may play a protective role in CRC. , n = 253; KRas G12D :Rasgrp1 −/− , n = 278). NS, not significant; * * * P < 0.0001 (one-way ANOVA, Bonferroni's).
Rasgrp1 regulates homeostasis of normal intestinal epithelial cells
Wnt signals at the bottom of intestinal crypts regulate self-renewal of stem cells and produced daughter cells undergo proliferation in response to EGFR signals, followed by terminal differentiation, migration and apoptosis 28 . In Drosophila, EGFR signalling is critical for intestinal maintenance 29, 30 . In the mouse, deficiency in Egfr results in disorganized crypts 31 and fine-tuning of EGFR signalling is critical to regulate proliferation in the intestinal stem cell niche 32 . In the human intestine, EGFR-Ras signalling occurs in progenitor cells in the transit-amplifying (T/A) zone in the intestinal crypts, where it is thought to control proliferation and differentiation 11 . Immunohistochemistry revealed Rasgrp1-positive cells in crypts (Fig. 2a) . Rasgrp1 −/− mice do not exhibit gross intestinal abnormalities but alterations may be revealed under circumstances of injury. We exposed Rasgrp1 −/− mice to a well-established model of colitis 33 . Remarkably, Rasgrp1
−/− mice showed partial protection from DSS (dextran sulphate sodium)-induced colitis (Fig. 2b,c) . The lack of T lymphocytes in Rasgrp1 −/− mice is unlikely to provide protection because DSS induces colitis in models devoid of T lymphocytes 33 . We postulated that protection could stem from an intrinsic difference in Rasgrp1 −/− epithelial cells. In vivo BrdU labelling at 2 h ( Fig. 2d ) and 48 h (Fig. 2e) revealed that colonic intestinal epithelial cells without Rasgrp1 proliferate more extensively compared with wild-type cells (Fig. 2f) . In the Rasgrp1-deficient small intestine, BrdU + cells were found at the top of the villus, 2 days after BrdU administration, whereas the furthest-progressed WT BrdU + cells positioned midway along the crypt-villus axis (Fig. 2g,h ). We also observed increased numbers of cleaved caspase-3-positive cells in Rasgrp1 −/− mice compared with WT mice (Fig. 2i,j) . Thus, Rasgrp1 deficiency alters normal intestinal homeostasis and leads to increased proliferation accompanied by increased apoptosis at the tip of the villi. Loss of Rasgrp1 resulted in small but consistent increases in mucus-producing goblet cells (Fig. 2k,l) , which may provide an additional explanation for the reduced DSS colitis in Rasgrp1 −/− mice.
Deletion of Rasgrp1 exacerbates intestinal dysplasia in
We next explored the role of RasGRP1 in the context of KRAS MUT , a somatic mutation found in ∼40% of CRC patients 5 . Expression of KRas G12D in the intestinal epithelium of mice produces aberrant cell proliferation and hyperplasia accompanied by relatively intact terminal differentiation [34] [35] [36] . We reduced the Rasgrp1 expression in VillinCre:KRas LSL-G12D mice 35 (termed KRas G12D here) by crossing them to Rasgrp1 −/− mice 17 . We used VillinCre mice as control (termed wild type-WT-here). Heterozygosity for Rasgrp1 results in half the Rasgrp1 protein dosage 37 , whereas Rasgrp1-deficient mice express no Rasgrp1 protein 17 ( Fig. 2a ). In the normal colon, proliferation is confined to cells in the bottom of the crypt. KRas G12D mice exhibited colonic crypt hyperplasia with increased numbers of proliferating cells further up in the differentiated zone, measured through Ki67 staining or in vivo BrdU labelling. Loss of Rasgrp1 resulted in a further augmentation of the KRas G12D -induced proliferation ( Fig. 3a-c and Supplementary  Fig. 1a,b) . Serrated dysplasia is a notable feature of the KRas G12D mouse colon and seen in KRAS MUT human hyperplastic polyps [34] [35] [36] ( Fig. 3a,b ). At 6 months of age, we found that loss of either one or both Rasgrp1 alleles resulted in exacerbated serrated dysplasia, typified by further lengthening and increased serration of villi-like projections into the colonic lumen, and accompanied by increased abundance of goblet cells (Fig. 3d ,e and Supplementary Fig. 1c ). The increased goblet cell presence and heavily serrated nature in these KRas G12D :Rasgrp1 WT /− and KRas G12D :Rasgrp1 −/− mice share remarkable resemblance with human hyperplastic or serrated polyps of the goblet cell subtype 38 , an important subcategory of hyperplastic polyps that provides a route to CRC distinct from conventional adenomas to CRC (ref. 38) .
In the normal small intestine, proliferation mainly takes place in the crypt and T/A zone, which is one epithelial cell layer thick 28 and the site of EGFR signalling 11 . Compared with WT controls, villi of KRas G12D small intestine were longer and had a branched appearance in 20% of the cases, as suggested previously 36 . Depletion of Rasgrp1 in the context of KRas G12D resulted in a more profound branching of the villi ( (Fig. 3l ,m,p,q). These characteristics are indicative of active cell division and used to type dysplastic tissues from patients 38 . Despite increases in proliferation, deletion of Rasgrp1 did not trigger further lengthening of already elongated KRas G12D villi nor did it lead to an overall increase in length of the intestinal track ( Supplementary Fig. 2c,d ). Instead, we observed increased levels of cleaved caspase-3 when Rasgrp1 is deleted in the context of KRas G12D (Fig. 3r,s) . As previously reported 36 , we did not see differences in apoptosis between KRas G12D and WT small intestines.
EGFR-RasGRP1 and EGFR-SOS1 signals in epithelial cells
Our genetic approach reveals that Rasgrp1 restricts the dysplastic effects of KRas G12D in the intestinal epithelium. To investigate the underlying mechanism, we first established RasGRP1 protein expression in 16 of 18 human CRC cell lines as well as EGFR expression (Fig. 4a) . Eleven of eighteen CRC cell lines carried the stereotypic KRAS MUT found in patients 5 . In stimulated lymphocytes, the GEF activity of RasGRP1 is enhanced through PKC-dependent phosphorylation 15 . We used the DT40 cell system to demonstrate that phospho-T 184 -RasGRP1 levels were induced on B-cell receptor-but also EGFR-stimulation in RasGRP-and PKC-dependent manners (Fig. 4b) . We subsequently immunoprecipitated RasGRP1 from KRAS WT SW48 and KRAS MUT HCT15 CRC cells, two lines of similar stage (Dukes' type C colorectal adenocarcinoma, ATCC information). EGF transiently elevated phosphorylation of RasGRP1 in both lines (Fig. 4c) . SOS1, pre-complexed with Grb2, is recruited to phosphorylated Tyr 1068 in EGFR (ref. 39 ) and subject to feedback that includes EGFinduced phosphorylation 40 . Consequently, EGFR stimulation induced a mobility shift of SOS1 in HCT15 and SW48 cells (Fig. 4d) . To investigate the RAF-MEK-ERK effectors pathway downstream of RasGTP, we examined ERK phosphorylation and noted that both cell lines exhibit EGF-induced activation of ERK kinases ( Fig. 4e ). RasGRP1 and SOS1 probably play roles in CRC cells with either a KRAS MUT or a KRAS WT allele, because both RasGEFs are phosphorylated in HCT15 and SW48 cells in response to EGF (Fig. 4f) .
KRAS
MUT CRC cell lines demonstrate EGFR-induced hyperactivation of RAS To investigate the mechanistic underpinnings of RasGRP1, SOS1 and KRAS MUT in the cellular response to signalling through EGFR, we selected seven CRC lines that represent each significant genotype (Supplementary Table 1 ). Expression of RasGRP1 in these cells is specific and selective; these cell lines express essentially no RasGRP3 or RasGRP4. RasGRP2, although expressed, for example, in CaCO 2 and SW48 ( Supplementary Fig. 3 ), is an exchange factor for the small GTPase Rap 15, 41 .
As expected from the impaired RasGAP-mediated inactivation of KRAS MUT (refs 1-3), lines carrying KRAS MUT exhibited elevated constitutive RAS-GTP levels compared with CaCO 2 , WiDr and SW48 cells with KRAS WT (Fig. 5a ). Low baseline KRAS-GTP levels were efficiently, but transiently, elevated by EGF stimulation of KRAS WT cell lines (Fig. 5b,d ). Significantly, elevated constitutive KRAS-GTP levels in KRAS MUT CRC cells were further increased by EGF stimulation (Fig. 5c,d ). This last observation, combined with our data in Fig. 4 ( Fig. 5i) Table 2 ). Reduction of SOS1 expression resulted in: less sustained KRAS activation following EGF stimulation, compared with controls (Fig. 6b) ; diminished in vitro colony formation, particularly noticeable when dependent on EGF (Fig. 6c,d) ; and reduced in vivo tumorigenesis when subcutaneously xenografted (Fig. 6e ). These results demonstrate that EGFR-SOS1-Ras signals contribute to tumorigenesis when CRC cells carry a KRAS MUT allele. Supplementary Fig. 7 . (c,d) Soft-agar colony formation assays of the indicated HCT15 cell populations that were grown in growth medium with 5% serum (c) or in serum-free medium supplemented with 10 ng ml −1 EGF (d). Fifteen fields pooled from 3 independent experiments were counted per condition (WT, n = 15; shRNA mSos1, n = 15; shRNA hSOS1, n = 15). Data are mean ± s.e.m. NS, not significant; * P < 0.05, * * * P < 0.0001 (one-way ANOVA, Bonferroni's multiple comparison test). (e) Relative tumour size of the indicated HCT15 cells xenografted into nude mice and measured 40 days after injection. WT, n = 7 mice; shRNA mSos1, n = 9; shRNA hSOS1, n = 10, all pooled from 2 independent experiments. Results are given as percentages with one WT arbitrarily set at 100%. Means with standard errors (±s.e.m.) are plotted. NS, not significant; * P < 0.05, * * * P < 0.0001 (unpaired t-test).
RasGRP1 restricts EGF-SOS1-induced KRAS-ERK signalling through negative feedback
We postulated that reduction of RasGRP1 expression in HCT15 cells (Fig. 7a) may have a different outcome, because RasGRP1 is structurally distinct from SOS1, is not activated allosterically by RAS-GTP, and possesses 1,000-fold lower intrinsic RasGEF activity 22 . A 53% reduction of RasGRP1 from HCT15 cells resulted in increased EGFR-driven hyperactivation of KRAS (Fig. 7b) , which translated into sustained ERK phosphorylation downstream of Ras-GTP (Fig. 7c,d and Supplementary Fig. 4a,b) .
We subsequently investigated whether RasGRP1 may impact SOS1. We examined levels of P-Y 1068 -EGFR (phospho-tyrosine 1068 in EGFR) a major auto-phosphorylation site 43 to which Grb2-SOS1 is recruited 39 , under conditions of EGF stimulation (Fig. 5i) . Reduction of RasGRP1 expression significantly and selectively increased P-Y 1068 -EGFR levels (Fig. 7e ) and increased levels of P-Y 1068 -EGFR complexed to SOS1-Grb2 (Fig. 7f) . RasGRP1 is recruited to the membrane by diacylglycerol 15 and enhancing diacylglycerol-RasGRP1 signalling in EGF-stimulated HCT15 cells through exposure to an inhibitor of the diacylglycerol-converting enzyme DGK (diacylglycerol kinase) 44 resulted in reduced P-Y 1068 -EGFR levels (Fig. 7g) . Thus, diacylglycerol-RasGRP1 signalling constitutes a negative feedback loop to limit P-Y 1068 -EGFR-Grb2-SOS-RAS-ERK signals.
Analogous to our findings in the human CRC HCT15 cell line, we observed that deletion of one or two alleles of Rasgrp1 in the context of KRas G12D substantially increased the relative staining for phosphorylated ERK kinases in sections of colonic epithelium (Fig. 7h) . Furthermore, direct, side-by-side comparisons of isolated epithelial cells confirmed the increased ERK phosphorylation in KRas G12D colonic epithelial cells when Rasgrp1 levels are reduced (Fig. 7i ).
RasGRP1 expression levels limit growth of KRAS MUT CRC cells
Reduction of RasGRP1 expression led to increased colony formation of HCT15 CRC cells in vitro, induced by either serum or by EGF (Fig. 8a,b) , and increased size and enhanced growth rate of xenografted tumours, compared with the parental HCT15 cells or HCT15 cells with a mouse Rasgrp1 short hairpin RNA (shRNA) construct as specificity controls (Fig. 8c,d) 48 to divide CRC patients into two groups based on RasGRP1 expression. We observed that high expression of RasGRP1 correlates with a better clinical outcome (Fig. 8e and Supplementary Fig. 5a,b) . Fig. 6c . NS, not significant; * * * P < 0.0001 (one-way ANOVA, Bonferroni's multiple comparison test). n = 15 fields pooled from 3 independent experiments were counted per condition (WT, n = 15; shRNA mSos1, n = 15; shRNA hSOS1, n = 15). Data are mean ± s.e.m. (c) Xenografted HCT15 cells were analysed as in Fig. 6e . WT, n = 9 mice; shRNA mRg1, n = 10; shRNA hRG1, n = 10; all pooled from 2 independent experiments. * P < 0.05 (unpaired ttest). (d) Growth rates of the indicated xenografted HCT15 cells. Specifics of HCT15 cells with shRNA hSOS1 are inserted in blue for comparison. Data are mean ± s.e.m. WT, n = 3; shRNA mRg1, n = 3; shRNA hRG1, n = 4; shRNA hSOS1, n = 4. (e) Kaplan-Meier survival curve for 172 patient samples with high RasGRP1 expression level (red line; n = 155 patients) and low RasGRP1 expression level (blue line; n = 17 patients) (P = 0.0243, logrank (Mantel-Cox) Test). Similar results were obtained with two independent studies 46,47 (see Supplementary Fig. 5a Min/+ mice were also deficient for Rasgrp1 (Fig. 8f) . As reported [50] [51] [52] , we found large numbers of tumours in the Apc Min/+ small intestine. Additional loss of Rasgrp1 did not lead to significant changes in tumour numbers or size in the small intestine (Fig. 8g,h ) but led to a significant increase in the number of colonic tumours, which rarely develop in Apc Min/+ mice (Fig. 8i,j) . Colonic tumours in Apc Min/+ :Rasgrp1 −/− or Apc Min/+ mice demonstrated a similar overall architecture (Fig. 8k and Supplementary Fig. 6a ) but exhibited increased individual tumour size (Fig. 8l) . In agreement, normal crypts and tumours of Apc Min/+ :Rasgrp1 −/− mice revealed increases in proliferative markers compared with Apc Min/+ mice (Fig. 8m ,n and Supplementary Fig. 6b ). Moreover, loss of Rasgrp1 resulted in significant increases in phospho-ERK signals in both the normal crypts and in tumours in the context of Apc Min/+ (Fig. 8o) . Cleaved caspase-3-positive, apoptotic cells were rare in Apc Min/+ tumours and remained sparse, although slightly increased, in tumours from Apc Min/+ :Rasgrp1 −/− mice ( Fig. 8p and Supplementary Fig. 6c ). Thus, RasGRP1 plays a suppressive role in CRC in the context of both KRAS MUT and Apc Min/+ by limiting proliferative ERK signals.
DISCUSSION
Here we revealed that RasGRP1 and SOS1, two structurally distinct RasGEFs (refs 19,22) , both lie downstream of EGFR. Reduction of RasGRP1 levels relieves the negative feedback to EGFR-SOS1, sustains EGFR-RAS-ERK signalling, and promotes cell proliferation. We find that RasGRP1 plays a negative regulatory role in CRC and that depletion of Rasgrp1 alleles exacerbates ERK signalling and serrated dysplasia and hyperproliferation of the KRas G12D intestinal epithelium. KRas G12D alone does not lead to full CRC in mice [34] [35] [36] . Consistent with the conclusion that perturbed Ras function by itself is insufficient to produce CRC, we did not observe highgrade dysplasia or adenocarcinomas in KRas G12D :Rasgrp1 WT /− and KRas G12D :Rasgrp1 −/− mice that were up to 9 months of age. Epithelial cells in these two models return to the normal simple columnar pattern further up the villus, despite the severely altered T/A zone, and loss of Rasgrp1 results in increased levels of cell apoptosis. For full CRC to develop in mice, KRas G12D requires additional events such as loss of the APC tumour suppressor 35 . Vice versa, perturbation of APC requires EGFR signalling for tumour maintenance 53, 54 . In agreement with the concept that these two pathways intersect in CRC, we observe that loss of Rasgrp1 in addition to the Apc Min/+ allele leads to increases in colonic tumour numbers and sizes and reduced mean survival of Apc Min/+ :Rasgrp1 −/− mice. RasGRP3 seems to connect to cMET(HGF)-signal input 55 . Our results here show that RasGRP1 responds to EGFR signal input. Thus, RasGRP RasGEFs can couple to receptor tyrosine kinases but the mechanistic details and the biological consequences are not yet fully understood. RasGRP3 promotes growth of melanoma-and prostatecancer cells 55, 56 whereas our findings here demonstrate that RasGRP1 opposes CRC growth. The suppressive function of RasGRP1 in CRC also contrasts its growth-promoting role in T-cell leukaemia 27 and in skin cancer 57 . Thus, not all RasGRP1-generated Ras signals are the same and RasGRP1 may function as a context-dependent tumoursuppressor protein or a protein with oncogenic functions.
Here we revealed non-intuitive feedback between two RasGEFs; that is, EGFR-RasGRP1 signals that dampen EGFR-SOS signals. Grb2 can impair access of phosphatases to the FGFR (refs 58,59) . Possibly, RasGRP1 indirectly promotes phosphatase access to EGFR, reducing Grb2-SOS1-P-Y 1068 -EGFR complexes. Alternatively, EGFR-RasGRP1 may influence phosphatase function directly. The phosphatase Cdc25A binds to and dephosphorylates EGFR (ref. 60) . Interestingly, vemurafenib (PLX4032) treatment of CRC cells with somatic BRAF(V600E) was recently shown to relieve a negative feedback loop to EGFR by decreasing the activity of the phosphatase Cdc25C, resulting in increased P-Y 1068 -EGFR levels 61 . It is of interest to note that somatic KRAS MUT emerge as mediators of acquired resistance to anti-EGFR therapy 62, 63 . Possibly anti-EGFR therapy inhibits the negative feedback coming from EGFR-RasGRP1 signals.
METHODS
Methods and any associated references are available in the online version of the paper. 
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METHODS
Bioinformatics and TCGA data mining. NCI-60 cell lines 26 , Cancer Cell Line Encyclopedia 64 and Colorectal Adenocarcinoma 65 databases were evaluated for RasGRP1 mRNA expression and copy levels. We used the bioinformatics tool 'cBio Cancer Genomics Portal' 25 to interrogate the above cancer genomic databases (www. cbioportal.org). We analysed RasGRP1 mRNA expression z-scores correlated with copy number level in NCI-60 cell lines, Cancer Cell Line Encyclopedia and The Cancer Genome Atlas (TCGA) Colorectal Adenocarcinoma, and we computed the KRAS mutation association z-score with RasGRP1 mRNA expression 25 . We compared RasGRP1 gene expression in human colon cancer and normal tissues using the Oncomine database (www.oncomine.org). Statistical analysis of the differences in RasGRP1 expression between these tissues used Oncomine standard algorithms: for each microarray, data were log 2 -transformed, median-centred, and standard deviation normalized 67 . The TCGA data set obtained from Oncomine is embedded in the TCGA database (https://tcga-data.nci.nih.gov/tcga).
To validate the correlation for RasGRP1 expression and patient outcome, three public colon cancer data sets (GSE17536 (ref. 45); GSE12945 (ref. 46) ; GSE14333 (ref. 47)) were downloaded from the NCBI GEO database (National Center for Biotechnology Information, Gene Expression Omnibus). Data were normalized using the Robust Multichip Average (RMA) and annotated in GEO (ref. 68) . A cutoff finder using the R statistical engine was performed to define two groups of patients with different survival curves using RasGRP1 gene expression (low or high) 48 . We analysed data at a follow-up time of ten years. The Kaplan-Meier estimator was used to evaluate patients' prognosis. The log-rank (Mantel-Cox) test was carried out to compare survival curves and to measure hazard ratios. Analyses were performed and graphs were generated using GraphPad Prism version 6.04.
Cell lines and reagents. Cell lines were cultured at 37 • C in 5% CO 2 .
Stable cell lines infected with lentivirus containing small hairpin RNA (shRNA) against SOS1 or RasGRP1 were selected with puromycin 10 µg ml −1 (Mediatech, Cellgro) and subsequently sorted for GFP levels. Cells were maintained under selection. Colorectal cancer (CRC) cell line mutational status was obtained from the Wellcome Trust Sanger Institute Cancer Genome Project website (http:// www.sanger.ac.uk/genetics/CGP) and verified by UCSF sequencing core facility (Supplementary Table 1 ). BrdU, DAPI and Alcian blue were purchased from SigmaAldrich, diacylglycerol kinase inhibitor II (R59949) was purchased from Enzo Life Science (Alexis) and dissolved in DMSO, human epithelial growth factor (hEGF) recombinant protein was purchased from Life Technologies and dissolved in PBS, and PKC inhibitor rottlerin was purchased from Calbiochem and dissolved in DMSO. LSL-G12D/+ mice (KRas G12D , here) previously described were kindly provided by T. Jacks (MIT). We crossed these mice to VillinCre transgenic mice to activate the mutant KRAS allele in the intestinal tract. This mouse was used as a control and noted WT. Progenies were then crossed to a Rasgrp1 knockout (Rasgrp1 −/− ) provided by J. Stone to generate a mouse expressing KRas G12D in the context of 1 and 2 Rasgrp1 alleles deleted KRas G12D :Rasgrp1 WT /− and KRas G12D :Rasgrp1 −/− respectively. Apc Min/+ mice were crossed to Rasgrp1 −/− mice to obtain complete deletion of Rasgrp1(Apc Min/+ :Rasgrp1 −/− ). Primers used for genotyping of Rasgrp1: Primer 1, 5 -GCAGCTGTCAATAAGATCATCCAGGC-3 ; primer 2, 5 -ATATTGCTGAAG AGCTTGGCGGCGAATGGG-3 ; primer 3, 5 -CTATCCTCACTTGAGTCTCTCT TTCC-3 . All other primers were recommended by Jackson laboratory.
The utilization of resected or biopsied liver metastases from primary CRC for the purpose of evaluation of potential biomarkers of clinical outcome was approved by the University of California San Francisco committee on Human Research and patient consent was obtained. Decoded CRC patient samples obtained from R.W. were analysed by the Roose group for RasGRP1 expression (CHR approval -Study Title: RasGRP1 in Human T cell lymphoma and CRC IRB no.: 12-09467; reference no.: 053353).
shRNA constructs and experiments. Knockdown of human RasGRP1 and human SOS1 has been described previously 11 . The oligonucleotide sequences are as follows. For mRasgrp1-1503: sense oligonucleotide, 5 -TGATCGCTGC AAGC-TTTCCATTCAAGAGATGGAAAGCTTGCAGCGATCTTTTTTC-3 ; antisense oligonucleotide, 5 -TCGAGAAAAAAGATCGCTGCAAGCTT-TCCA TCTCTTGAATGGAAAGCTTGCAGCGATCA-3 . For hRasGRP1-1503: sense oligonucleotide, 5 -TGATT--GCTGCG--AGT--TTTCCATTCA-AGAGATGG AAAACTCGCAGCAATCTTTTTTC-3 ; antisense oligonucleotide, 5 -TCGAG AAAAAAGATTGCTGCGAGTTTTCCATCTC-TTGAATGGAAAACTCGC AGCAATCA-3 . Targeting of the 1503 region was based on previous work 21 . The hRasGRP1-1503 targets human RasGRP1, has three mismatches with the same sequence in mRasgrp1-1503, and served as a specificity control. CRC cell lines were seeded in 24-well plates and infected with lentivirus (5MOI) with Polybrene through standard spin infections (1,044g for 1 h) and selected on puromycin (10 µg ml −1 ) 48 h after infection. Similarly, SOS was targeted as described previously 11 . hSOS1-1313 targets human SOS1, has two mismatches with the same sequence in mSos1-1313, and served as a specificity control. RNA extraction and real-time PCR. Total RNA was isolated from human tissue and cell lines using RNeasy kit (Qiagen). RNA was reverse-transcribed with random primers (Invitrogen) and Moloney murine leukaemia virus reverse transcriptase. Real-time PCR was performed in triplicate using Eppendorf RealPlex2. Gene expression was normalized to that of GAPDH and quantified with the comparative CT method according to the manufacturer's instructions. The following combinations of primers and probes were used to analyse the expression of human RasGRP1: forward, 5 -AAGCTCCACCAACTACAGAACT-3 ; reverse, 5 -A GGGAGATGAGGTCCTTGAGAT-3 ; probe, FAM-5 -CCACATGAAATCAATA AGGTTCTCGGTGAG-3 -TAMRA and human GAPDH forward, 5 -GAAGGTGA AGGTCGGAGT-3 ; reverse, 5 -GAAGATGGTGATGGGATTTC-3 ; probe, FAM-5 -AGGCTGAGAACGGGAAGCTTGT-3 -TAMRA. RasGRP2, 3 and 4 probes and primers were obtained at Applied Bio System. For patient samples the sample size (n = 30) was based on the number of samples with high-quality RNA.
Western blot. Cells were plated in 6 or 10 cm dishes and starved for 2 h at 37 • C in PBS. After resting, cells were EGF-stimulated for different times: 3, 10 or 30 min. Cells were lysed with ice-cold 2% NP40 supplemented with protease and phosphatase inhibitors (10 mM sodium fluoride, 2 mM sodium orthovanadate, 0.5 mM EDTA, 2 mM phenylmethylsulphonyl fluoride, 1 mM sodium molybdate, aprotinin (10 mg ml −1 ), leupeptin (10 mg ml −1 ), pepstatin (1 mg ml −1 )). After 30 min on ice, lysates were centrifuged and the supernatants were mixed with 2× sample buffer. Protein lysates were separated on acrylamide gel 10%, transferred on PVDF membrane and incubated with the primary antibodies of interest. Inhibitors such as rottlerin (20 µM) and DGK were pre-incubated for 30 min before stimulation. Western blots were visualized with enhanced chemo-luminescence and imaging on a Fuji LAS 4000 image station (GE Healthcare). The protein bands in western blots were quantified with Multi Gauge software, and densitometry (pixel intensity) was determined within the linear range of the exposure. Amounts of the proteins of interest were typically presented as a ratio of the indicated loading control. Values were then normalized to an indicated sample and noted as a fold difference.
Ras pulldown assay. Activation of Ras was analysed by a Ras-GTP pulldown assay. Cells were rested in PBS with Ca/Mg in 6-well plates at 37 • C for 2 h and stimulated with 5 ng ml −1 hEGF for 3 and 10 min. Cells were then lysed with icecold 1x MLB for pulldowns (Millipore) and scraped. Twenty per cent of the lysate was used for whole-cell lysate and 80% was used for pulldown according to the manufacturer's instructions (Upstate). Lysates were loaded on precast bis-tris gel 4-12% (Invitrogen). Membranes were incubated with primary antibody and specific signals have been quantified as described in the western blot paragraph.
3, 10 or 30 min and lysed in 1% NP40 as described above. The supernatant was split into 2 parts. 20% was used for whole-cell lysates and 80% was incubated with antihuman SOS1 and tumbled for 2 h at 4 • C. The G-Sepharose beads (GE Healthcare) were added and tumbled for 50 min at 4 • C. After several washes using 1% NP40, sample buffer was added before being boiled and loaded on acrylamide gels 8% and 10%. Results represent at least three independent experiments. Isolation of intestinal epithelial cells. Methods were adapted from ref. 69 . In short, large intestines were dissected, rinsed with PBS, opened and cut into 1-2 cm fragments before incubation in a conical tube with PBS. Debris was removed by PBS washes and fragments were transferred to clean tubes containing pre-warmed PBS with 2.5 mM EDTA. Fifteen-min incubations at 37 • C in a water bath and removal of supernatant containing epithelial cells at crypt structures were repeated 2-3 times and cells were collected by centrifugation at 311g and cells were lysed in NP40 lysis buffer to extract proteins.
Extraction of colonic epithelium and tumours. Colon of mice were dissected and washed with PBS. Tumours were isolated and flash-frozen. Healthy tissues adjacent to tumours were collected to serve as controls. Tissues were incubated in 200 µl of 1× RIPA buffer on ice and homogenized using an electric dounce. Lysates were process as described elsewhere. Protein quantification was evaluated using BCA assay (Thermo Scientific).
Soft-agar colony formation assay. Colorectal cell lines were seeded (1 × 10 5 ) in duplicate into 60-mm cell culture dishes in 1 ml of 0.3% agar (Noble agar, SIGMA) in RPMI containing 5% FBS, 1% penicillin/streptomycin, 1% glutamine, and 2.37 g l −1 Na 2 CO 3 , on top of a layer of 1 ml of 1% agar. For complete culture conditions, normal culture media was added and changed every other day. Cultures were maintained for 15 days. For the EGF condition, hEGF (10 ng ml −1 ) was added to minimal culture media. Colonies were fixed with 70% ethanol and stained with 0.005% crystal violet. Colonies were visualized, and at least 5 randomly chosen fields were photographed with a Nikon DXM1200 digital camera coupled to a light microscope. Results are a combination of three-independent experiments. Xenograft mouse studies. HCT15 cells with or without shRNA (2 × 10 5 ) were injected subcutaneously into the flank of 6-to 8-week-old male Nude-Foxn1nu mice (n = 5 at least per group; Harlan lab). Tumour volume was determined by external calliper measurement every other day as soon as it reached a palpable size. Calculation was carried out as follows: tumour volume = 1/2(length × width 2 ). Mice were monitored daily for body weight and general condition. According to institutional guidelines, mice were euthanized when their tumour volume reached 2,000 mm 3 or became excessively ulcerated. Experiments were repeated twice with 5 mice in each group, experiments were not randomized. Pilot studies guided our choice of sample size and gave an indication of the difference to be expected between experimental samples in the eventual experiments.
Dextran sodium sulphate-induced colitis. DSS (3%, MP Biomedicals) was added to the drinking water of co-housed, 10-12-week-old C57Bl6 and Rasgrp1 −/− mice for 5 days. Mice were assessed daily for diarrhoea, bloody stools and body weight. At day 5, mice were euthanized and the small and large intestines were processed as described in the immunohistochemistry section. DSS damage scores were determined by the sum of three parameters as previously described 66 : surface epithelial loss, crypt destruction, and inflammatory cell infiltration into the mucosa. A score of '0' represents no change, '1' localized and mild change, '2' localized and moderate change, '3' extensive and moderate change, '4' extensive and severe change.
Immunohistochemistry. Tissues were dissected, fixed in 4% PFA and paraffinembedded. Then 5-µm-thick sections were de-waxed in Histo-Clear (National Diagnostics) and rehydrated in graded alcohol baths. Antigen retrieval was performed in a pressure cooker for 20 min in 10 mM sodium citrate buffer, pH 6.0. For cleaved caspase-3 staining, a solution of 10 mM TRIS with 1 mM EDTA pH 9 was used. Endogenous peroxidase activity was inhibited with 1.5% H 2 O 2 in methanol for 20 min and washed in PBS. Nonspecific binding sites were blocked in blocking buffer (PBS, pH 7.4, 3% serum, 1% BSA and 0.1% Tween) for 60 min at room temperature. Sections were then incubated with primary antibodies diluted in blocking buffer overnight at 4 • C. Slides were then washed twice with 0.1% PBS-Tween before incubation in Universal Immuno-peroxidase polymer antimouse/rabbit Histofine for mouse tissues (Nichirei Biosciences) was used as a secondary reagent. Stainings were visualized with DAB (3,3 -diaminobenzidine, Sigma-Aldrich) and a haematoxylin counterstain (Sigma-Aldrich) was performed before dehydration. After dehydration, sections were mounted in Cytoseal 60 (Thermo Scientific). To study the structure of tissue, haematoxylin & eosin (H&E) staining was performed. For quantification, images were acquired using a Nikon Optiphot microscope equipped with an AxioCam HR at fixed exposure (objective ×20 and ×40). For BrdU experiments, mice were injected intraperitoneally (2 mg per 200 µl) for 2 h or 48 h. To detect goblet cells, slides were treated with Alcian blue (pH 2.5) for 30 min and counterstained using Nuclear red (Sigma-Aldrich) followed by standard mounting techniques.
Immunofluorescence. Tissues were dissected, fixed in 4% PFA, incubated overnight at 4 • C in sucrose 30% and embedded in OCT (Tissue-Tek)/sucrose 30% (2 vol/1 vol). Sections (10-µm-thick; Cryostat Leica) were dried and washed in PBS. After a 0.1% PBS-Tween (Sigma-Aldrich) wash, the sections were incubated in blocking buffer (1% BSA, 3% normal goat serum and 0.2% Triton X-100-PBS) for 1 h at room temperature. Sections were then incubated with primary antibodies diluted in blocking buffer overnight at 4 • C and washed twice with 0.1% PBSTween and PBS before incubation in secondary antibody conjugated with Alexa 546 (Molecular Probes, Life technologies) and DAPI in PBS-Triton X-100 0.5% (Sigma-Aldrich) for 45 min at room temperature. Slides were washed twice with PBS before mounting with mounting medium (Dako). Images were taken by using a micro-lensed, spinning disk confocal scan-head coupled to a motorized, inverted fluorescence microscope (Zeiss Axiovert 200M; Carl Zeiss). Images were collected using an ICCD camera (XR-Mega-10EX S-30, Stanford Photonics). For villi lengths, pictures were taken and the length of the villi in the duodenum was determined using ImageJ software. Pixel values were transformed into metric values using a microscope scale. Fifty villi were counted and values are representative of three mice per genotype. All data were represented as mean ± s.e.m. For xenograft experiments, damage score after DSS treatment, and immunostainings, unpaired t-tests were used for two-group comparisons. For comparisons of phospho-ERK immunoblot quantification in Apc Min/+ mice, a paired t-test was applied. All specific statistical analyses are mentioned in the respective paragraphs. Counting for Ki67 staining, brdU, goblet cells, cleaved caspase-3 and branching villi, was done blind. In all other experiments, a one-way ANOVA followed by a Bonferroni post hoc test was used for comparisons of three or more groups. For all tests, a P value of <0.05 was considered statistically significant. Analyses and graphs were done using Prism 5 software. Table 1 . WiDr was used as an arbitrary reference and set at 1.0. All data are shown as fold difference ± s.e.m and compared to the value of 1.0 in WiDr and data is plotted from n = 6 independent RNA extractions for each cell type. 3b, Same data sets for WiDr and SW403 as in Supplementary figure 3a but depicted on a different scale to highlight low expression of RasGRP1 in WiDr and nearly complete absence of RasGRP1 in SW403 CRC cells. WiDr was used as an arbitrary reference and set at 1.0. All data are shown as fold difference ± s.e.m and compared to the value of 1.0 in WiDr and data is plotted from n = 6 independent RNA extractions for each cell type. 3c-3e. RasGRP2-(c), RasGRP3-(d) and RasGRP4-(e) mRNA expression levels in the indicated seven CRC cell lines. WiDr was used as an arbitrary reference and set at 1.0. All data are shown as fold difference ± s.e.m and compared to the value of 1.0 in WiDr and data is plotted from n = 6 independent RNA extractions for each cell type.
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